Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VER-01 versus opioid therapy in chronic non-specific low back pain
2022-001358-41Phase 3Completed
- Sponsor
- Vertanical
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of VER-01 in Low back pain (LBP) (2 arms), sponsored by Vertanical. Primary endpoint: Constipation responders at end of treatment. Started Oct 2022; status: completed.
02
Drugs
VER-01
03
Conditions
Low back pain (LBP)
Beyond the preview
Go deeper on 2022-001358-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001358-41.